No abstract

Purpose: The goal of this study was to evaluate the clinical effect of propolis gel associated with non surgical therapy in the management of chronic periodontitis. Subjects and Methods: Thirty chronic periodontitis patients were selected in this study with probing depth not less than 5 mm in each site. Patients randomly divided into three groups ten subjects on each. Patients in Group1 were treated with scaling and root planning and local delivery of propolis gel with chitosan polymer. Patients in group 2 were treated with non surgical therapy and propolis gel with polyox polymer. Patients in group 3 were treated with non surgical therapy alone. The clinical parameters were assessed at baseline, 1 month and 3 months. Results: Clinical parameters showed a favorable improvement in group received propolis gel with polyox polymer than the group received propolis gel containing chitosan polymer. Conclusion: Adjunctive use of propolis with polyox polymer to non surgical therapy showed favorable results over use of propolis with chitosan polymer in patients with chronic periodontitis.

Itopride hydrochloride (ITO HCl) is a prokinetic agent, used in the treatment of gastrointestinal motility disorders. The aim of the study was to develop stable mucoadhesive thermoreversible nasal gel to avoid first pass effect. ITO HCl was incorporated into the blends of thermoreversible polymers like poloxamer 407 and various mucoadhesive polymers in different concentrations to increase the contact of the formulations with nasal mucosa. The compatibility between the drug and the suggested polymers was studied by Fourier transform infrared and differential scanning calorimetry (DSC). The formulations were evaluated for clarity, pH, gelation temperature, mucoadhesive strength, gel strength, viscosity, and drug content. In addition, the in vitro drug release and the dissolution efficiency (DE)% were measured. The optimized formulations that showed the highest dissolution efficiency% (DE%) in saline phosphate buffer of pH 6.4 at 35 ± 0.5 °C were chosen for stability testing at temperatures of 4 ± 2 and 25 ± 2 °C/60 ± 5% RH. It was found that F1 and F17 that contain 18% w/v poloxamer 407 and 0.5% w/v of hydroxypropylmethyl cellulose K4M or methyl cellulose (MC), respectively, showed higher stability results as indicated by their higher t values (days).

No abstract

Trifluoperaizne (TFP) is an antipsychotic medication with limited oral bioavailability due to extensive first-pass metabolism; consequently, the goal of this project was to develop Leciplex nanoparticles to improve the bioavailability of TFP and to prolong its nasal residence time for treatment of the depression. Leciplex NPs were prepared using negatively charged phospholipid, cationic surfactant and biocompatible solvent and optimized using the 21 31 full factorial statistical design using various surfactants and different phospholipid to surfactant ratios. Design Expert® software was employed to select the optimum formula. The formulae were characterized regarding their particle size (PS), polydispersity index (PDI), zeta potential (ZP), entrapment efficiency percentages (EE %), amount of drug released after 6 hours (Q6h), transmission electron microscopy analysis, fourier transform infrared ray spectroscopy (FT-IR) and stability for six months. Optimized formula was contained dimethyldidodecylammonium bromide as surfactant and had a

Hepatic first-pass metabolism has been a major cause of reduced bioavailability for many drugs. Using the nasal route as an alternative route to deliver drugs to the systemic circulation provided the solution to this problem. One of the drugs which are highly affected by first-pass metabolism is itopride hydrochloride (ITO HCl). It is a prokinetic agent used for the treatment of various gastrointestinal motility disorders, mainly gastroesophageal reflux. The objective of this study was to determine the pharmacokinetic parameters of selected mucoadhesive in situ nasal gel formulations (F1 and F17) of itopride hydrochloride (ITO HCl) and to evaluate their safety after topical application on the nasal mucosa. The tested formulations contained 18% w/v poloxamer 407 with 0.5% w/v of HPMC K4M (F1), or with 0.5% w/v MC (F17). A randomized cross-over study was done on six rabbits after administration of F1, F17, and commercial oral tablets (Ganaton®). Plasma levels were assessed using high-performance liquid chromatography (HPLC) to compare the nasal gel formulations with the conventional oral tablets. Histopathological study of the nasal mucosa was performed in rats after nasal application of both in situ gel formulas. The in vivo pharmacokinetic profiles of in situ nasal gel formulas F1 and F17 provided showed improvement in Cmax, Ke, t1/2, AUC0–24, AUC24–inf, AUC0–inf, AUMC24–inf, AUMC0–inf, MRT, Vd, and Cmax/AUC0–24 values over commercial tablets (p < 0.05). No statistically significant difference was found between both nasal gel formulas (F1 and F17). The percentage relative bioavailability of ITO HCl nasal in situ gel F1 and F17 was found to be 171.22% and 178.91%, respectively, in comparison with the commercial tablet. Histopathological study of the nasal mucosa revealed the safety of nasal in situ gel formulations to the nasal mucosa after 14 days of application. The study showed that the formulation of itopride hydrochloride as a mucoadhesive in situ nasal gel has enhanced the drug bioavailability due to avoidance of first-pass metabolism. The study points to the potential of mucoadhesive nasal in situ gel in terms of safety and efficiency.

Background: The goal of this study was to clinically evaluate the effect of propolis gel in different polymeric systems as an adjunct to non-surgical therapy in the management of periodontitis patients. Methods: A total of 30 patients with stage III grade B periodontitis were divided into the following three groups: group I patients, who received propolis in a chitosan polymer gel with non-surgical therapy, group II patients, who received propolis in a polyox polymer gel with non-surgical therapy, and group III patients who served as a control treated with non-surgical therapy only. Clinical parameters were assessed at baseline, one month, and three months. Results: At three months, the mean gingival index (GI) of groups I and II was the same (0.6 ±0.52), and there was no change in the mean GI in group III. There was a reduction in the mean probing depth (PD) in group I (4.80 ±0.63) and group II (4.90 ±0.74) at the end of the study. The greatest percent gain in clinical attachment level (CAL) was noted in group II (17.26 ±6.71) followed by group I (5.93 ±9.87), whereas the least percent decrease was noted in group III (3.67 ±7.77). Conclusion: The adjunctive use of propolis in a polyox polymer with non-surgical therapy demonstrated superior clinical results over the use of propolis in a chitosan polymer in periodontitis patients.